Drug Profile


Alternative Names: Hypoxin™; PR 610; Tarlox; Tarloxotinib bromide; TH-4000

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Auckland
  • Developer Proacta; Threshold Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 21 May 2018 Rain Therapeutics plans a proof-of-concept phase II trial for Non-small cell lung cancer in the first half of 2019
  • 03 Aug 2017 Chemical structure information added
  • 29 Jun 2017 Tarloxotinib is available for licensing as of 29 Jun 2017. http://www.thresholdpharm.com/overview-1/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top